drugset
drugset / Trial / NCT02361242

24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion

NCT02361242 ↗

Phase 2 Completed 45 enrolled Pharnext S.C.A. Ascopharm Groupe Novasco · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

PLEODIAL-II study is an extension of the previous pilot PLEODIAL-I study (CLN-PXT00864-03 protocol) and is designed for the descriptive analysis of patients with mild AD who are exposed to PXT00864 over an additional 24-week period.

Timeline

Start
2013-06
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Acamprosate Small molecule 0.4 mg Oral
Subject Acamprosate Small molecule 1 mg Oral
Subject Acamprosate Small molecule 20 mg Oral
Subject Baclofen Small molecule 6 mg Oral
Subject Baclofen Small molecule 12 mg Oral
Subject Baclofen Small molecule 15 mg Oral

Indications

Alzheimer disease